RTOG Foundation Study 3503
Status Date: October 15, 2019 | Status: Completed
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Manmeet Ahluwalia, MD
To determine the efficacy of TTFields Therapy with bevacizumab as measured by the overall survival rate at 6 months from the time of registration.
Confirmation of recurrence or progression on contract MRI of histologically proven GBM or other grade IV malignant glioma.
|Emory University, Winship Cancer Institute||Atlanta||GA|
|Froedert and Medical College of Wisconsin||Menomonee Falls||WI|
|Medical University of South Carolina||Charleston||SC|
|University of California San Diego Moores Cancer Center||La Jolla||CA|
|University of Florida Health Cancer Center||Orlando||FL|
|University of California Irvine, Chao Family Comprehensive Cancer Center||Orange||CA|
|University of Rochester||Rochester||NY|
|Washington University School of Medicine||St. Louis||MO|